deltatrials
Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03415867

Glasdegib in Refractory Patients With Sclerotic Chronic Graft-Versus-Host Disease

A Phase 1b/ 2a Pilot Trial of the Oral Hedgehog Signalling Inhibitor Glasdegib in Patients With Sclerotic Chronic Graft-Versus-Host Disease Refractory to Second-Line Treatment

Sponsor: Grupo Espanol de trasplantes hematopoyeticos y terapia celular

Conditions Sclerodermoid Chronic Graft-Versus-Host Disease (Disorder)
Interventions Glasdegib
Updated 13 times since 2018 Last updated: Mar 16, 2022 Started: Jan 9, 2018 Primary completion: Jan 9, 2022 Completion: Jun 9, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Sclerodermoid Chronic Graft-Versus-Host Disease (Disorder), this trial is ongoing. The trial is conducted by Grupo Espanol de trasplantes hematopoyeticos y terapia celular and has accumulated 13 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Sep 2019 · 15 months · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Jan 2021 · 12 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Apr 2022 · 7 months · monthly snapshot~Apr 2022 – ~Apr 2024 · 24 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE1/PHASE2

    Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Apr 2024 — Jul 2024 [monthly]

    Unknown Status PHASE1_PHASE2

    Status: Active Not Recruiting → Unknown Status

  4. Apr 2022 — Apr 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Sep 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 8 earlier versions

  1. May 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Jan 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Dec 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Nov 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Sep 2019 — Nov 2019 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jun 2018 — Sep 2019 [monthly]

    Recruiting PHASE1_PHASE2

  8. Feb 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Jan 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Data source: Grupo Espanol de trasplantes hematopoyeticos y terapia celular

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations